Expanding women’s fertility lifespan
Expanding women’s fertility lifespan
For too long, eggs ageing has been a frustrating roadblock for those seeking fertility treatments. With our innovative approach, we are changing the game. By targeting the root cause of the problem, we are able to elevate eggs quality and provide hope for those struggling to conceive.
Our lab discovered the mechanism underlying cell ageing and created a novel compound that rejuvenates women's egg cells (oocytes), increase by twofold the number of eggs available per IVF cycle.
This novel preclinical compound therapy, seamlessly integrated into existing IVF protocols, doubles viable egg yield and boosts success rates. We reduce the number of cycles needed, drug treatments, and costs for 3+ million IVF journeys per year.
Over 95% of women seeking assisted reproductive technology opt for IVF, nevertheless IVF results are questionable, 23.7% of live births for patients aged 38-40 years, falling to 7.6% for patients over 40 years.